Compare Illumina, Inc. (ILMN) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Teladoc Health Inc — how do they compare? Illumina, Inc. trades at $189.68 (market cap $27.94B), while Teladoc Health Inc trades at $9.58 (market cap $1.74B). The key difference: Illumina, Inc. is far larger — about 16.1× Teladoc Health Inc's market cap. Which is the better fit depends on your goals.
| ILMN | TDOC | |
|---|---|---|
Market Cap | $27.94B | $1.74B |
Sector | Health | Health |
52-Week High | $194.33 | $9.72 |
52-Week Low | $91.00 | $4.47 |
Enterprise Value | $29.33B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TDOC trades at $9.63, up 2.12% today, with a bullish technical signal from moving averages and a neutral RSI near 60. Revenue remains stable around $2.5 billion, but net losses persist with a -6.81% margin. Recent news highlights expansion through the Walmart partnership and upcoming Q2 2026 earnings. The stock shows resilience despite negative profitability, supported by a low P/S ratio of 0.67 and improving cash flow trends from operations.
Outlook is mixed: cost-cutting and partnerships offer growth potential, but sustained losses and high debt pose risks. Analysts are cautious with a $8.75 price target below current levels, reflecting concerns over profitability. Investors should weigh the recovery narrative against financial challenges, with earnings on July 29, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
